Photo of Keyan Salari, MD, PhD

Keyan Salari, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital


ksalari@mgh.harvard.edu

Photo of Keyan Salari, MD, PhD

Massachusetts General Hospital


ksalari@mgh.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Keyan Salari, MD, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Keyan Salari, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Surgery, Harvard Medical School
  • Assistant in Urology, Urology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am surgeon-scientist at Massachusetts General Hospital and Harvard Medical School, where I have a clinical practice as a urologic oncologist in the MGH Department of Urology and MGH Cancer Center. My research interests focus on leveraging a variety of genomic techniques and computational biology methods to advance precision cancer medicine in genitourinary malignancies. Our research aims to improve early detection of clinically significant prostate cancer and distinguish indolent from aggressive disease to guide treatment decisions.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Chahine SY, Alkhatib KY, Arakelyan G, Buxton C, Giannarini G, Hamilton RJ, Holt SK, Bernhard JC, Jiang DM, Lin D, Liu JJ, Manley B, Master VA, Matveev V, Necchi A, Packiam VT, Patel SH, Peak T, Peyton CC, Pierorazio PM, Prakash G, Salari K, Sexton WJ, Singla N, Spiess PE, Psutka SP. Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management. Eur Urol Focus 2024. PubMed
  • Rumpf F, Plym A, Vaselkiv JB, Penney KL, Preston MA, Kibel AS, Mucci LA, Salari K. Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer. J Urol 2024. PubMed
  • Amini AE, Hunter AE, Almashad A, Feng AJ, Patel ND, O'Dea MR, McCormick SR, Rodgers LH, Salari K. Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study. Eur Urol Oncol 2024. PubMed
  • Amini AE, Salari K. Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology. JCO Precis Oncol 2024; 8:e2300560. PubMed
  • Mei S, Alchahin AM, Tsea I, Kfoury Y, Hirz T, Jeffries NE, Zhao T, Xu Y, Zhang H, Sarkar H, Wu S, Subtelny AO, Johnsen JI, Zhang Y, Salari K, Wu CL, Randolph MA, Scadden DT, Dahl DM, Shin J, Kharchenko PV, Saylor PJ, Sykes DB, Baryawno N. Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions. Genome Med 2024; 16:1. PubMed
  • D'Andrea V, Jason Qian Z, Yim K, Egan J, Magnani CJ, Feldman A, Salari K, Tewari A, Steele G, Mossanen M, Preston M, Chang SL, Clinton TN. Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer. Urol Oncol 2023. PubMed
  • Yim K, Melnick K, Mott SL, Carvalho FLF, Zafar A, Clinton TN, Mossanen M, Steele GS, Hirsch M, Rizzo N, Wu CL, Mouw KW, Wszolek M, Salari K, Feldman A, Kibel AS, O'Donnell MA, Preston MA. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol 2023. PubMed
  • Salari K, Sundi D, Lee JJ, Wu S, Wu CL, DiFiore G, Yan QR, Pienkny A, Lee CK, Oberlin D, Barme G, Piser J, Kahn R, Collins E, Phillips KG, Caruso VM, Goudarzi M, Garcia-Ransom M, Lentz PS, Evans-Holm ME, MacBride AR, Fischer DS, Haddadzadeh IJ, Mazzarella BC, Gray JW, Koppie TM, Bicocca VT, Levin TG, Lotan Y, Feldman AS. Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction. Clin Cancer Res 2023. PubMed
  • Schneider AC, Chandrasekar T, Bowler N, Fogg R, Leong JY, Gusev A, Rodgers LH, McCormick SR, Dahl DM, Efstathiou JA, Blute ML, Zietman AL, Wu CL, Smith MR, Van Allen EM, Feldman AS, Salari K. Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer. J Urol 2023; 209:1112-1119. PubMed
  • Salari K, Kowitz J, Twum-Ampofo J, Gusev A, O'Shea A, Anderson MA, Harisinghani M, Kuppermann D, Dahl DM, Efstathiou JA, Lee RJ, Blute ML, Zietman AL, Feldman AS. Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer. Urol Oncol 2023. PubMed
  • Dason S, Mohebali J, Blute ML, Salari K. Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. Urol Clin North Am 2023; 50:261-284. PubMed
  • Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K, Murray E, Chen F, Macosko EZ, Wu CL, Scadden DT, Dahl DM, Baryawno N, Saylor PJ, Kharchenko PV, Sykes DB. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun 2023; 14:663. PubMed
  • Egan J, Salari K. Biomarkers in Testicular Cancer: Classic Tumor Markers and Beyond. Urol Clin North Am 2023; 50:133-143. PubMed
  • Nayan M, Salari K, Bozzo A, Ganglberger W, Carvalho F, Feldman AS, Trinh QD. Predicting survival after radical prostatectomy: Variation of machine learning performance by race. Prostate 2021; 81:1355-1364. PubMed
  • Nayan M, Salari K, Bozzo A, Ganglberger W, Lu G, Carvalho F, Gusev A, Schneider A, Westover BM, Feldman AS. A machine learning approach to predict progression on active surveillance for prostate cancer. Urol Oncol 2021. PubMed
  • Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, AlDubayan SH, Salari K, Kregel S, Richter C, Arnoff TE, Park J, Hahn WC, Van Allen EM. Biologically informed deep neural network for prostate cancer discovery. Nature 2021; 598:348-352. PubMed
  • Ng TSC, Gao X, Salari K, Zlatev DV, Heidari P, Kamran SC. Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective. 2021; 11:722277. PubMed
  • He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med 2021; 27:426-433. PubMed
  • Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, Lee R, Chughtai B, Olumi AF, Mosquera JM, Demichelis F, Elemento O, Rubin MA, Sboner A, Barbieri CE. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun 2020; 11:1987. PubMed
  • AlDubayan SH, Conway JR, Camp SY, Witkowski L, Kofman E, Reardon B, Han S, Moore N, Elmarakeby H, Salari K, Choudhry H, Al-Rubaish AM, Al-Sulaiman AA, Al-Ali AK, Taylor-Weiner A, Van Allen EM. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma. JAMA 2020; 324:1957-1969. PubMed
  • Hanna N, Wszolek MF, Mojtahed A, Nicaise E, Wu B, Gelpi-Hammerschmidt FJ, Salari K, Dahl DM, Blute ML, Harisinghani M, Feldman AS. MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER. J Urol 2019. PubMed
  • Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol 2019; 201:721-727. PubMed
  • Wang Z, Hu L, Salari K, Bechis S, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Douglas SW, Olumi AF. Androgenic to estrogenic switch in human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. J Pathol 2017. PubMed
  • Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci U S A 2012; 109:E3196-205. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Keyan Salari, MD, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members